From lab to bedside: emerging clinical applications of thymosin alpha 1
Goldstein A.L.
Editor's note
Goldstein's own four-decade overview of thymosin alpha-1 — approved abroad as Zadaxin for hepatitis B/C, sepsis, and as an oncology adjuvant. Useful framing for what the peptide is actually doing immunologically; the US clinical-trial column remains thin.